Drugs Submission Guide
Drugs's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Drugs, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Drugs
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Drugs accepts roughly Proposal and invitation led of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Drugs
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Topic timing |
2. Package | Prepare inquiry |
3. Cover letter | Contact editorial office |
4. Final check | Editorial appraisal |
Quick answer: This Drugs journal submission guide is for clinical-pharmacology researchers evaluating their proposed Review against the journal's clinical-relevance bar.
Springer Nature's Adis imprint primarily commissions Reviews from invited authors; unsolicited proposals enter as presubmission inquiries. The editorial standard requires direct clinical prescribing relevance and sustained author authority in the clinical-pharmacology subfield.
Run a Drugs pre-submission readiness check before clicking submit, or work through this guide manually.
From our manuscript review practice
Of presubmission inquiries we've reviewed for Drugs journal, the most consistent decline trigger is topic framing for basic science rather than clinical prescribing relevance.
How this page was reviewed
This page was researched from Drugs journal's author guidelines, Adis editorial-policy materials, Clarivate JCR data, and Manusights internal analysis of presubmission inquiries.
Source limitations: Springer Nature publishes the current submission-guideline page, journal scope, editorial policies, and article-type framework. It does not publish invitation-planning notes or proposal-level decline reasons. Manusights observations are anonymized pre-submission review patterns and are included only as practical author guidance.
After the official guidance, the practical screen is the set of failure patterns we see when the inquiry letter, outline, clinical question, author-authority statement, reference map, and cover letter do not support a clinical-prescribing Review.
For the underlying journal profile, see Drugs.
What are Drugs journal metrics?
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | 14.4 |
5-Year JIF | ~14+ |
CiteScore | 22.5 |
Functional Acceptance Rate (post-invitation) | High |
Presubmission-Inquiry Approval Rate | ~15-20% |
Time from invitation to publication | 9-15 months |
Publisher | Adis (Springer Nature) |
Source: Clarivate JCR 2024, Adis editorial disclosures (accessed April 2026).
What are Drugs journal submission process and timeline?
Stage | Details |
|---|---|
Presubmission inquiry | Required for unsolicited Review proposals |
Inquiry portal | Direct contact to editorial office |
Inquiry length | 1-2 page outline with author authority statement |
Inquiry decision | 2-4 weeks |
Manuscript invitation | Following inquiry approval |
Manuscript delivery | 4-9 months from invitation acceptance |
Review and revision | 2-4 months |
Review article length | 6,000-12,000 words, 100-200 references |
Source: Drugs author guidelines.
What should the inquiry snapshot prove?
What to pressure-test | What should already be true before contact |
|---|---|
Clinical-prescribing relevance | Review provides direct guidance for clinical practice |
Author authority | Sustained primary-research and clinical experience in the pharmacology subfield |
Topic timing | No comparable Drugs Review in the prior 3-5 years |
Synthesis value | Topic supports practice-relevant synthesis |
Inquiry letter | Establishes clinical-relevance, author authority, and timing case |
What this page is for
Use this page when deciding:
- whether the proposed Review has clinical-prescribing relevance
- whether the author team has sustained authority in the clinical-pharmacology subfield
- whether topic timing is right
What should already be in the inquiry
- a clear clinical-prescribing-relevant synthesis
- author authority with primary-research and clinical-pharmacology experience
- topic-timing case
- direct contribution to clinical pharmacology
- a 1-2 page outline with author authority statement
Inquiry mistakes that trigger early decline
- Topic recently covered in Drugs.
- Author standing in basic pharmacology rather than clinical pharmacology.
- Scope framed as basic-science synthesis rather than clinical-prescribing-relevant Review.
- Clinical-prescribing relevance is peripheral.
What makes Drugs journal a distinct target
Drugs is among the highest-impact clinical-pharmacology journals.
Clinical-prescribing focus: the journal differentiates from Pharmacological Reviews (basic-pharmacology focus) and Clinical Pharmacology and Therapeutics (broader scope) by demanding direct clinical-prescribing relevance.
Authority expectation: editors weigh clinical-pharmacology authority and clinical experience.
Long planning horizon: invitations often planned 12-18 months ahead.
What should a strong inquiry letter sound like?
The strongest Drugs inquiry letters establish:
- the clinical-prescribing-relevant synthesis in one sentence
- the author authority with clinical-pharmacology record
- the topic-timing case
- the practice relevance
How should authors diagnose pre-inquiry problems?
Problem | Fix |
|---|---|
Topic recently covered | Find a clearly distinct angle |
Author authority is in basic pharmacology | Recruit clinical co-author with prescribing experience |
Synthesis framed as basic science | Articulate the clinical-prescribing relevance |
How Drugs compares against nearby alternatives
Method note: the comparison reflects published author guidelines and Manusights internal analysis. We have not personally been Drugs authors; the boundary is publicly documented editorial behavior. Pros and cons are based on documented editorial scope.
Factor | Drugs | Pharmacological Reviews | Clinical Pharmacology and Therapeutics | Drug Safety |
|---|---|---|---|---|
Best fit (pros) | Clinical-prescribing-relevant Reviews | Basic-pharmacology Reviews | Original clinical pharmacology research | Drug safety focus |
Think twice if (cons) | Topic is basic pharmacology | Topic is clinical-prescribing focused | Topic is comprehensive Review | Topic is broader pharmacology |
Submission portal
Drugs (Adis/Springer) submissions go through the Adis submission system at Adis submission system. Initial setup requires an Adis account; ORCID is recommended for the corresponding author. The platform accepts unsolicited Original Research Articles (up to 6,000 words), Summary of Research Articles (SRA) format submissions (standalone summaries of source articles previously published in an Adis journal or another publisher), and Letters to the Editor (up to 1,000 words). Full guide at Drugs Submission Guidelines.
Submission checklist
Drugs requires these at first submission:
- Cover letter explicitly establishing the clinical aspects of drug treatment and the strong link to clinical practice (the journal weights clinical-prescribing relevance heavily)
- Declaration of competing interests for all authors (especially pharmaceutical industry consulting, equity positions, and patent holdings)
- Ethics approval statement for any human-subject research with explicit IRB approval reference
- Informed consent statement for human-subject research
- Data availability statement with repository links for clinical trial data, pharmacokinetic measurements, or systematic review search records
- ICMJE / WAME / COPE compliance statement (Adis endorses these editorial conduct codes)
- Good Publication Practice (GPP) compliance statement for any sponsored research
- CRediT author contributions statement
- For SRA submissions: reference to the source article and explicit licensing context
- For revisions of previously peer-reviewed manuscripts from other journals: copy of prior referee comments and authors' response (the journal editor explicitly assesses how prior comments have been addressed)
- Manuscript within the 6,000-word cap for Original Research Articles or the 1,000-word cap for Letters
For Drugs submissions, the most common artifact-related issue is missing GPP compliance documentation for industry-sponsored research. Adis editors check this at the initial appraisal stage; submissions with industry funding that lack the GPP statement are commonly returned for completion before scope screen.
Readiness check
Run the scan while Drugs's requirements are in front of you.
See how this manuscript scores against Drugs's requirements before you submit.
Editorial triage timeline
For Drugs submissions, the editorial timeline runs through four phases. The journal editor performs an initial appraisal of each manuscript, and unsuitable submissions may be assessed for transfer to other Adis journals by appropriate editors (a distinctive cross-journal transfer pathway).
Day 0 to 7: Adis submission system intake and editor initial appraisal
The journal editor performs an initial appraisal handling format compliance plus the ethics-statement, GPP-compliance, and prior-review documentation checks. The handling Editor assignment lands within 7 days; clinical-pharmacology papers route to subject editors matching the therapeutic area (cardiovascular, oncology, infectious disease, neurology, immunology, metabolic disease). The most common Day 0-7 hold-up: missing GPP statements for industry-sponsored research.
Day 7 to 28: Editor scope and clinical-relevance screen
Drugs' editor filter prioritizes clinical aspects of drug treatment with strong links to clinical practice. The most common Day 7-28 desk reject in our review work: preclinical mechanism-of-action studies without clinical-application framing, pure-pharmacology papers without prescribing-decision relevance, and basic discovery work that should have gone to Drug Discovery Today or a discovery-focused journal. Manuscripts unsuitable for Drugs may be assessed for transfer to other Adis journals (Drugs & Aging, Clinical Pharmacokinetics, Drug Safety, Drugs in R&D) without authors needing to resubmit separately.
Week 4 to 10: Peer review
Standard 2-3 reviewers per Adis policy, 4-8 week first decision target. Reviewer mix typically includes one clinical-pharmacology specialist plus one therapeutic-domain expert or evidence-synthesis methodologist. Submissions missing comparator-drug efficacy benchmarks, pharmacokinetic context, or systematic-review methodology documentation extend reviewer dialogue by 3-5 weeks.
Week 10 to 22: Decision, revision, and production
Major or minor revision is the standard first decision at Drugs. Revision rounds typically settle at 2 (rarely 3 for accepted papers). Total submission-to-acceptance: 5-8 months for accepted papers. Open-access option available through Springer Open Choice with APC at acceptance.
Submit (inquire) If
- the synthesis is clinical-prescribing relevant
- the author team has clinical-pharmacology authority
- the topic-timing case is strong
- practice relevance is direct
Think Twice If
- the proposed outline overlaps recent Drugs coverage and the abstract cannot name a new clinical-prescribing decision
- the author statement and references show basic pharmacology strength but limited clinical-pharmacology authority
- the inquiry letter reads like a mechanistic review instead of a cover letter for prescribing-relevant synthesis
What to read next
- Is Drugs journal a good journal?
Before contacting, run your proposal through a Drugs journal presubmission readiness check.
Read the public instructions for mechanics, then pressure-test the package the way an editor will see it. The review tells you whether your paper clears the Drugs fit check before upload, especially around topic proposal that collides with recent Drugs coverage, author authority that is scientific but not clinical-prescribing credible, and inquiry framed as basic pharmacology rather than a prescribing decision. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.
Decision risks before submitting to Drugs
Across Manusights submission reviews for Review proposals targeting Drugs, three patterns generate the most consistent inquiry declines. They are visible in the inquiry letter, outline, clinical question, author-authority paragraph, reference map, and proposed figures or tables before a full manuscript exists.
Topic proposal that collides with recent Drugs coverage
For Drugs proposals, the most common avoidable problem is topic timing. The inquiry letter proposes a Review on a drug class, indication, mechanism, or treatment strategy that Drugs or a close Adis title has already covered recently. The outline may be competent, the authors may be credible, and the references may be current, but the proposal does not explain why readers need this Review now. The manuscript components that reveal the risk are the title, outline headings, recent-reference map, proposed tables, and author-authority statement.
The stronger inquiry begins with a timing argument. It should identify the clinical-prescribing decision that has changed since the last major Review, such as new trial data, updated safety signals, guideline movement, comparative-effectiveness questions, real-world evidence, label changes, or unresolved sequencing decisions. The outline should not look like a general encyclopedia entry. It should show how the Review will help clinicians choose, monitor, combine, avoid, or sequence therapies.
If the proposal cannot distinguish itself from recent Drugs, Clinical Pharmacokinetics, CNS Drugs, Targeted Oncology, Pharmacological Reviews, or Clinical Pharmacology & Therapeutics coverage, the timing case is weak.
A Drugs presubmission readiness check can identify whether the inquiry letter, outline, references, and proposed tables make the timing case clear enough before you contact the journal.
Check topic proposal that collides with recent drugs coverage before submitting to Drugs →
Author authority that is scientific but not clinical-prescribing credible
Drugs is not simply a high-impact pharmacology venue. In Manusights reviews, proposals often fail because the author team has strong laboratory, molecular, or pharmacology credentials but insufficient evidence of clinical-prescribing authority for the exact topic. The CV may show publications, but the inquiry letter does not show that the team can synthesize comparative efficacy, safety, dosing, monitoring, populations, contraindications, or guideline-relevant decision points. That gap is especially visible in the author-authority paragraph and the proposed table list.
The stronger proposal makes authority specific. It names the authors' sustained work in the drug class, disease area, clinical pharmacology problem, systematic-review evidence base, guideline space, or prescribing population. If the lead authors are basic scientists, the package should include a clinical co-author who understands treatment decisions. If the proposal covers a rapidly changing therapeutic area, the reference map should show command of recent trials, regulatory changes, and safety discussions.
If the paper is a narrative Review, the outline still needs a transparent logic for source selection and interpretation.
This is where adjacent routing matters. Pharmacological Reviews may be better for mechanism-heavy synthesis. Clinical Pharmacology & Therapeutics may be better for translational clinical pharmacology and policy-facing work. CNS Drugs, Targeted Oncology, or BioDrugs may own topic-specific audiences. Drugs is strongest when the Review helps clinicians and clinical pharmacologists interpret drug therapy in practice.
Inquiry framed as basic pharmacology rather than a prescribing decision
The third failure mode is a mismatch between the scientific content and the editorial promise. We see proposals whose outline begins with molecular pharmacology, receptor biology, preclinical models, or mechanism-of-action history, then adds clinical relevance at the end. That structure can work for a basic-pharmacology Review, but it is risky for Drugs when the title, abstract-style summary, proposed figures, and cover letter do not foreground a clinical-prescribing question.
The stronger inquiry reverses the order. It starts with a clinician-facing problem: which patients benefit, which risk groups need monitoring, how therapies compare, when to switch, how safety changes use, or where evidence remains uncertain. Mechanism belongs in the outline only where it clarifies clinical action. The proposed tables should be decision tools: comparative trials, approved indications, safety warnings, drug interactions, population-specific dosing, monitoring considerations, or treatment sequencing. The cover letter should say what decision the Review will improve.
If the proposal cannot be rewritten around a prescribing decision, a basic pharmacology, translational medicine, or specialty therapeutic journal may be a more honest target. Drugs submissions are strongest when the inquiry letter, outline, author team, and reference map all show clinical-pharmacology judgment.
Check your Drugs proposal against clinical prescribing substance before submission →
Frequently asked questions
Drugs primarily commissions Reviews from invited authors. Unsolicited proposals are accepted as presubmission inquiries to the editorial office. The journal accepts Reviews, Adis Drug Evaluations, and Therapy in Practice articles. The cover letter should establish the clinical-pharmacology contribution.
Authoritative Reviews on clinical pharmacology, drug therapy, drug safety, and Adis Drug Evaluations on individual drugs. The journal serves the clinical-pharmacology and prescribing-physician community with practice-relevant synthesis.
Drugs' 2024 impact factor is around 14.4. Functional acceptance rate at the presubmission-inquiry stage runs ~15-20%; once invited, completion-and-publication rates are high.
Most declines involve topic timing (recent overlapping coverage), author authority gaps in the proposed clinical-pharmacology subfield, scope mismatch with the journal's clinical-relevance focus, or proposals framed as basic-science syntheses rather than clinical-prescribing-relevant Reviews.
Sources
Final step
Submitting to Drugs?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Drugs
Anthropic Privacy Partner. Zero-retention manuscript processing.